The Claim
Engineered Escherichia coli expressing surface-displayed ClbS reduces colibactin-induced tumorigenesis by 50–70% in Apc Min/+ mice with colitis, as measured by macroscopic tumor count, when co-administered with pks+ E. coli NC101.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A genetically modified strain of E. coli bacteria, designed to produce a specific protein, reduces tumor formation by half to two-thirds in mice with intestinal inflammation and a genetic predisposition to colon cancer, when given alongside a cancer-promoting bacterial strain.
See the scientific wording
Engineered Escherichia coli expressing surface-displayed ClbS reduces colibactin-induced tumorigenesis by 50–70% in Apc Min/+ mice with colitis, as measured by macroscopic tumor count, when co-administered with pks+ E. coli NC101, demonstrating a potential preventive strategy for colitis-associated colorectal cancer.
What the research says
1 studyStudy: Surface expression of antitoxin on engineered bacteria neutralizes genotoxic colibactin in the gut
Scientists modified harmless gut bacteria to carry a special protein that neutralizes a cancer-causing toxin made by other bad bacteria. When they gave these modified bacteria to mice with gut inflammation and cancer-prone genes, the mice developed far fewer tumors.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.